SciELO - Scientific Electronic Library Online

vol.35 número4Experiencias emocionales en la interrupción voluntaria del embarazoSobre la pornografía y la educación sexual: ¿puede «el sexo» legitimar la humillación y la violencia? índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados




Links relacionados

  • Em processo de indexaçãoCitado por Google
  • Não possue artigos similaresSimilares em SciELO
  • Em processo de indexaçãoSimilares em Google


Gaceta Sanitaria

versão impressa ISSN 0213-9111


CUENDE, Natividad et al. The regenerative medicine and stem cell business: confusion with legal implications. Gac Sanit [online]. 2021, vol.35, n.4, pp.374-378.  Epub 27-Dez-2021. ISSN 0213-9111.

The rise of regenerative medicine and the growth of the offer of autologous therapies, obtained from blood, cells or tissues of the patients, have been favoured by the current availability of an increasing number of commercial devices. Most of these devices are easy to use, allowing the elaboration of products and its application within the same procedure. Regardless of the questionable efficacy and safety of many of the treatments offered under the claim of stem cells or regenerative medicine, most of the centres and professionals offering these treatments are unaware of the legal requirements and implications of their use. A common confusion consists in not distinguishing between the authorization required by the equipment itself, considered a medical device, and the authorization for the use of the product obtained, usually considered a medicinal product (whether advanced therapy or not) or a transplant. Moreover, these treatments frequently have an experimental nature. In that case, in addition to requiring the corresponding ethical evaluation and the authorization of various regulatory bodies, their administration must be offered free of charge, obtaining the patient's informed consent and after contracting a specific insurance policy. In this article we present a brief summary of the main requirements for the application of these autologous biological products with the aim of serving as a guide both for the professionals who prescribe them and for those who inspect the centres where the products are administered. Finally, we include some recommendations for patients.

Palavras-chave : Regenerative medicine Stem cells; Cell therapy; Platelet-rich plasma; Health law; Consumer product safety; Products commerce; Biosafety.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )